Welcome to our dedicated page for QuidelOrtho SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QuidelOrtho's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QuidelOrtho's regulatory disclosures and financial reporting.
QuidelOrtho Corporation beneficial ownership disclosure: Newtyn Management, LLC reports beneficial ownership of 5,300,000 shares of common stock, representing 7.8% of the class as of April 29, 2026. The filing states this total reflects holdings of Newtyn TE Partners, LP (3,418,500 shares) and Newtyn Partners, LP (1,881,500 shares), with the aggregate percentage calculated from approximately 68,081,767 shares outstanding as of February 11, 2026.
QuidelOrtho Corporation ownership disclosure: Newtyn Management, LLC reports beneficial ownership of 4,558,472 shares of QuidelOrtho common stock, representing 6.7% of the class. The filing states this aggregate position combines holdings of Newtyn TE Partners, LP (2,921,980 shares) and Newtyn Partners, LP (1,636,492 shares) as of March 31, 2026. The 6.7% figure is calculated using 68,081,767 shares outstanding as of February 11, 2026, per the issuer's 10-K.
QuidelOrtho Corp was reported as having 6,591,151.54 shares beneficially owned by FMR LLC, representing 9.7% of the common stock as of 03/31/2026. The filing (Schedule 13G/A Amendment No. 2) lists sole dispositive power of 6,591,151.54 shares and sole voting power of 6,587,889 shares. The cover shows CUSIP 219798105 and identifies Abigail P. Johnson in a related reporting capacity.
QuidelOrtho Corporation reported weaker Q1 2026 results, with an 11% revenue decline to $619.8 million and a much larger net loss of $91.8 million, or $1.35 per share. Revenue fell mainly in U.S. respiratory testing and Donor Screening, and from terminating a Joint Business with Grifols.
Cost of sales rose to 57.4% of revenue, and higher selling, marketing and administrative expenses and interest costs contributed to an operating loss of $31.8 million and loss before income taxes of $79.5 million. Operating cash flow swung from a $65.6 million inflow in Q1 2025 to a $33.0 million outflow.
The company ended the quarter with $140.4 million in cash and $2.69 billion of total borrowings, and remained in compliance with credit covenants. It is executing a multi‑year Optimization Plan targeting about $50 million of net savings by 2027 and is winding down its U.S. donor screening portfolio. After quarter‑end, QuidelOrtho agreed to acquire LEX Diagnostics for about $100 million in cash plus up to $35 million in earn‑outs.
QuidelOrtho Corporation reported weaker first quarter 2026 results with lower revenue, higher losses and reduced full-year guidance. Total revenue was $619.8 million, down 10.5% from $692.8 million a year earlier. Point of Care revenue fell 34% to $112.8 million, mainly from a weaker respiratory season, while Labs revenue declined 5.3% to $353.1 million amid slower China distributor sales, Middle East disruption and the end of a Grifols arrangement. Immunohematology grew 7.6% to $138.3 million.
GAAP net loss widened to $91.8 million from $12.7 million, with GAAP diluted loss per share of $1.35 versus $0.19. Adjusted EBITDA fell to $108.7 million from $159.8 million, and adjusted EBITDA margin declined to 17.5% from 23.1%.
For full-year 2026, the company now expects total revenue of $2.70–$2.75 billion, adjusted EBITDA of $615–$630 million, adjusted diluted EPS of $1.80–$2.00 and free cash flow of $100–$120 million, all lower than prior guidance. Management highlighted the April acquisition of LEX Diagnostics and new assay and platform launches as key elements of its long-term growth strategy.
QuidelOrtho Corp Schedule 13G shows Vanguard Capital Management beneficially owns 3,572,563 shares of common stock, representing 5.24% of the class. The filing states Vanguard has sole dispositive power over 3,572,563 shares and sole voting power over 519,853 shares. The filing attributes holdings to Vanguard Capital Management LLC and affiliated business divisions in accordance with SEC Release No. 34-39538.
QuidelOrtho Corp ownership filing: Vanguard Portfolio Management reports beneficial ownership of 4,088,168 shares of common stock, representing 6% of the class as of 03/31/2026. The filer reports 56,400 shares of sole voting power and sole dispositive power over 4,088,168 shares. The filing is signed on 04/29/2026.
QuidelOrtho Corp executive Bryan Michael Hanson, EVP Global Portfolio Management & Marketing, reported routine equity compensation activity. On April 26, 2026, 1,459 restricted stock units vested and converted into the same number of common shares, as previously disclosed on a Form 3. To cover related tax withholding obligations, 528 common shares were withheld by the company at a reference price of $11.59 per share, a non-market disposition. Following these transactions, Hanson directly holds 4,070 shares of QuidelOrtho common stock.
QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported routine equity compensation activity involving restricted stock units and related tax withholding. On April 26, 2026, 1,946 restricted stock units were released and converted into the same number of common shares at no cost, increasing his direct holdings.
To cover tax withholding obligations tied to this vesting, 699 common shares were withheld and disposed of at a value of $11.59 per share, a non‑market, tax-driven transaction. After these transactions, McLellan directly held 22,497 shares of QuidelOrtho common stock.